Buscar
Fibrobiologics Inc
FBLGAñadir a la lista de seguimiento
0.700USD
-0.019-2.67%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
2.46MCap. mercado
PérdidaP/E TTM
Más Datos de Fibrobiologics Inc Compañía
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Información de Fibrobiologics Inc
Símbolo de cotizaciónFBLG
Nombre de la empresaFibrobiologics Inc
Fecha de salida a bolsaJan 31, 2024
Director ejecutivoO'Heeron (Pete)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección455 E. Medical Center Blvd
CiudadHOUSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal77598
Teléfono12816715150
Sitio Webhttps://fibrobiologics.com/
Símbolo de cotizaciónFBLG
Fecha de salida a bolsaJan 31, 2024
Director ejecutivoO'Heeron (Pete)
Ejecutivos de Fibrobiologics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
9.00K
--
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
3.06K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
375.00
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
9.00K
--
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
3.06K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
375.00
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Fibrobiologics Inc?
Los cinco principales accionistas de Fibrobiologics Inc son: Mr. Ruben Garcia
¿Cuántas instituciones poseen acciones de Fibrobiologics Inc (FBLG)?
A fecha de 2026Q1, 139 instituciones poseen acciones de Fibrobiologics Inc, con un valor de mercado combinado de aproximadamente 258.88K, lo que representa el 4.97% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -83813.00.